Description:

ODM derived from http://clinicaltrials.gov/show/NCT00684619

Link:

http://clinicaltrials.gov/show/NCT00684619

Keywords:
Versions (1) ▾
  1. 12/9/13
Uploaded on:

December 9, 2013

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Eligibility NCT00684619 T-ALL, T-NHL (Lymphoblastic)

Eligibility

  1. StudyEvent: Eligibility
    1. Eligibility
Inclusion Criteria
age at least 18 Years
T-ALL, T-NHL
cytological treatment failure / relapse
molecular treatment failure / relapse
no promising therapy alternatives with approved medication available
no CNS-manifestation, requiring intrathecal therapy or CNS-radiation
no convulsive disease or neurotoxicity > grade III in patients history
written informed consent
no cytostatic therapy in the last 10 days
no pregnancy or breastfeeding
Contraception, Birth control
recovery of toxicities of previous chemotherapy - except leukemia-related changes like bone marrow suppression or pathological transaminases in liver manifestation
Exclusion Criteria
Severe psychiatric illness
uncontrolled or severe cardiac disease or infection
active secondary neoplasms - except skin cancer (no melanoma)